We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
At West, one of our core values is passion for customers. Their success is ultimately our success. Understanding our customers’ unique challenges and focus areas, ultimately helps us to better provide solutions for their needs. Recently, the West China Commercial Team visited one of our major local customers, Wuxi Biologics, and hosted its first large-scale on-site customer event, “Innovation Day.” As one of our major local customers, Wuxi Biologics is a leading company in China’s prosperous biopharmaceutical industry. The event drew over 140 participants and expanded our strategic collaboration, which will help us further support Wuxi Biologics with their specific drug development needs.
With the release of the "Outline of the Healthy China 2030 Plan", there are increasing development opportunities in the healthcare industry across China, especially in the area of biomedicine and life health. Research firms expect that the mainland biotech market will be worth US$96 billion by 2023 (from US$40 billion in 2018)1.
Stricter regulations and higher requirements go hand in hand with the thriving market. Pharmaceutical and biotechnology companies are facing challenges in terms of safety, efficacy, and effectiveness during the entire drug life cycle. As a trusted partner to established and emerging drug developers, West helps our customers to manage these ever-changing market needs and demands through consistent delivery of innovative solutions and services.
The agenda for the “Innovation Day” customer event, included high-level vision sharing and keynote speeches customized for the needs of Wuxi Biologics, as well as a key products exhibition. The event was focused on exchanging knowledge and experience and was warmly welcomed by the Wuxi Biologics team.
Zhang Jingwei, Vice President of Global Strategic Operation, Wuxi Biologics commented: “West has always been a trusted partner of WuXi Biologics. The event was very successful, and many of our colleagues have benefited a lot. I hope we can further strengthen strategic cooperation with West on product and service innovation, to meet our growing needs with newer technology, higher quality, faster speed, and more flexible services in the future.”
“We are pleased to bring West’s almost 100 years of experience and reputation on innovative and high-quality injectable solutions and services to Wuxi Biologics. We will continue to stand by the side of our customers to improve health for patients in China and worldwide.” said Philip Wang, General Manager, West China.
“It was really a fruitful event that not only helped us better understand customer needs, but also further established West’s leadership on solutions and technology,” said Philip Wang, General Manager, China, “I’d like to express my gratitude to every team member involved for living the values on Passion for Customers, Leadership in Quality and One West Team!”
Click here to learn more about West and be sure to follow us on WeChat by searching "WestPharmaceutical" for our latest updates.
1 From Innovation to Revolution: Chinese Biotech Industry, March 2020,https://www.am.miraeasset.com.hk/insight/innovation-revolution-chinese-biotech/
A key element of West’s commitment to a safe and efficient delivery of drug products is staying abreast of industry developments, and being prepared to help customers navigate them. Recently Dow Corning introduced a new product - Dow Corning® 366 35% Dimethicone NF Emulsion.
In 2011, the US FDA issued an advisory regarding the potential formation of glass lamellae in vials containing injectable drugs. This was in response to several drug recalls in 2010-11. The number of glass-related drug recalls has since declined greatly. This no doubt is due to key actions taken by pharmaceutical manufacturers before the drug goes to market, even during the development phases.
The pharmaceutical industry’s focus on extractables and leachables from packaging/delivery systems began during the mid-1990’s. Today’s regulatory agencies are more educated about the process, and drug product formulations have become more complex, which makes the need for robust extractables and leachables programs more critical than ever. In fact, failure to properly evaluate extractables and leachables has had a negative impact on many pharmaceutical companies, e.g., late-stage stability failures, submission delays, and recalls. To avoid this, the first question to ask is – “where do I start?”
Understanding the different compendial and standards requirements, and how they influence the final delivery of parenteral drug products, is critical for ensuring patient safety. There are ongoing efforts to harmonize national pharmacopoeia and international standards, driven in large measure by the continuous technological developments in the pharmaceutical industry. Harmonization efforts can be treated differently depending upon the country and working group, and in some cases larger differences result. Staying aware of changes and differences can be a challenge.
I’m coming towards the end of my 19th year at West in May this year. Today, I am the Global Facility Energy Manager, working as part of the Global Facility Engineering team. Previously, I joined the West Dublin site as a Maintenance Technician and after two years I was promoted to Facilities and Maintenance Manager.
English
Chinese
